S258: Lisocabtagene Maraleucel (Liso-Cel) as Second-Line Therapy for R/R Large B-Cell Lymphoma (Lbcl) in Patients Not Intended for Hsct: Primary Analysis From the Phase 2 Pilot Study

Sehgal, Alison R.; Hoda, Daanish; Riedell, Peter A.; Ghosh, Nilanjan; Hamadani, Mehdi; Godwin, John; Reagan, Patrick M.; Wagner‐Johnston, Nina D.; Essell, James; Nath, Rajneesh; Solomon, Scott R.; Champion, Rebecca; Licitra, E.; Fanning, Suzanne R.; Gupta, Neel K.; Dubowy, Ronald L.; D’Andrea, Aleco; Wang, L.; Gordon, L. I.

doi:10.1097/01.hs9.0000843924.40372.62

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, although no OS difference was again seen in this study, a trend was noted with liso‐cel (HR, 0.51; 95% CI, 0.26–1.0; p = .026). As mentioned earlier, liso‐cel is now approved for DLBCL in the second‐line transplant‐eligible and ‐ineligible populations on the basis of the TRANSFORM data plus the recently published PILOT study, in which additional efficacy and safety benefits were demonstrated with liso‐cel for transplant‐ineligible patients 8 …”

Section: Aggressive Lymphomasmentioning

confidence: 99%

See 1 more Smart Citation

Top advances in lymphoma for 2021

Patel

Kahl

2022

Cancer

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T‐cell therapy, antibody–drug conjugates, bispecific T‐cell redirectors, and agents targeting tonic B‐cell receptor signaling have altered the paradigm for three of the most common lymphomas in the year 2021. For diffuse large B‐cell lymphoma, the POLARIX study has shown improvement on the standard backbone of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in the frontline setting, a feat that had not been achieved despite great efforts over the past 20 years. In the relapsed and refractory setting, two unique CAR T‐cell products have displaced autologous transplantation to the third line, and they allow patients with chemotherapy‐resistant disease to receive approved therapy earlier. CAR T‐cell products, once used exclusively in the aggressive lymphoma arena, are now showing high response rates and durable activity against indolent lymphomas. The investigation of mosunetuzumab in indolent lymphomas offers another option for patients who have received multiple lines of cytotoxic drugs. On the basis of these trends, PI3K inhibitors are being displaced in favor of safer and more durable constructs. In addition, within the past year, the approval and implementation of zanubrutinib for marginal zone lymphoma have filled a need for later line therapy, especially for less fit and elderly patients.

show abstract

Section: Aggressive Lymphomasmentioning

confidence: 99%

“…As mentioned earlier, lisocel is now approved for DLBCL in the second-line transplant-eligible and -ineligible populations on the basis of the TRANSFORM data plus the recently published PILOT study, in which additional efficacy and safety benefits were demonstrated with liso-cel for transplantineligible patients. 8…”

Section: Introductionmentioning

confidence: 99%